Allergist Circassia grabs a couple of Asthma-Specialist companies

18/05/2015 - 2 minutes

The allergy specialist Circassia will acquire two asthma-expert companies: Aerocrine and Prosonix. The British company, which performed the biggest of the fifteen European biotech IPOs in 2014, intends to become a self-sustaining biopharma by focusing on allergies and asthma. The purchases will optimize the launch of CAT-Spire, which represents Circassia’s first drug of a new class of allergy treatments.

Circassia will disburse a total amount of €190.2 M (SEK 1.78 billion) to acquire Swedish Aerocrine and up to €138.1 M (£100 M) for British Prosonix, whose portfolio complements Circassia’s pipeline. Prosonix’s near-term products targeting asthma and other respiratory diseases will benefit from Aerocrine’s established commercial network.

Circassia will also use Aerocrine’s commercial infrastructure to launch CAT-Spire, its most advanced new class of allergy treatments. The drug was developed using Circassia’s ToleroMune technology and is currently undergoing the final phase of clinical testing.

ToleroMune technology, a unique approach to developing allergy immunotherapy treatments, was initially developed at the Imperial College London by Professors Mark Larché and Barry Kay,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!